WO2007085238A2

WO2007085238A2 - Multifunctional mixture of active substances

Info

Publication number: WO2007085238A2
Application number: PCT/DE2007/000134
Authority: WO
Inventors: Egon Tech
Original assignee: Egon Tech
Priority date: 2006-01-24
Filing date: 2007-01-22
Publication date: 2007-08-02
Also published as: DE102006051941A1; DE202007019590U1; DE112007000709A5; WO2007085238A3

Abstract

The invention relates to multifunctional mixtures of active substances that have preventive and therapeutic properties. Methods for producing said mixtures make use of the latest findings regarding quantum control while taking advantage of the behavior of biomolecules and minerals in an electromagnetic field. The invention also relates to the use of said mixtures of active substances as universal adjuvants for producing efficient vaccines against viral and cancer diseases. The invention further relates to the use of the disclosed multifunctional mixtures of active substances during the production of pharmaceutical compositions used for treating a wide spectrum of medical indications.

Description

Multifunctional active ingredient mixture

The invention relates to multifunctional active substance mixtures with preventive and therapeutic properties, as well as processes for their production, and to the use of these active substance mixtures. The active ingredient mixtures are used, inter alia, as a universal adjuvants, furthermore in the preparation of pharmaceutical compositions for the treatment of blunt nerve pathologies, as well as all indications, as in the TCM (Traditional Chinese Medicine), acupuncture of the meridians of various origins to restore the conduction and the Restoration of disturbed biofuels find use. Areas of application of the invention are biological research, applied biological research and the pharmaceutical industry.

introduction

Further developments in the field of nanotechnology and applied quantum physics open the possibility for the production of a new spectrum of active ingredient mixtures. Such active substance mixtures and their applications, inter alia as universal adjuvants, are the subject of the present invention. An adjuvant is a vaccine-added substance that has little antigenicity on its own but that stimulates the immune system to increase its response to the vaccine.

In addition to the actual active substance, in particular the administration method has a significant influence on the effectiveness of pharmaceutical compositions. In the context of the present invention, novel administration methods for the abovementioned mixtures of active substances are described. These new methods of administration include the AKUJECTUR (Registered Trade Mark, E.Tech) method, which, in addition to being relevant to the present invention, is of crucial importance to the advancement of traditional Chinese medicine methods. The philosophy of TCM and applied nanotechnology, combined with the latest findings in quantum physics, are reflected in the slogan "Better Quality of Life-General Direct Response" (BEQUOL-GDR, registered trademark, E.Tech). The object of the present invention was therefore to provide new multifunctional active substance mixtures, using methods, the latest findings of physical phenomena of quantum control, associated with behaviors of biologicals and minerals and their chosen complexes in the EMF (Electro Magnetic Field) and their novel, so far exploit unknown modes of action on the organism, as well as to provide new methods for producing efficient vaccines and adjuvants for vaccination against viral or cancer diseases.

This object is achieved according to claims 1, 5 and 6, the dependent claims are preferred variants.

The core of the invention is a multifunctional active substance mixture comprising

a fraction of specific peptides with molecular weights up to 10,000 daltons and a fraction of essential and nonessential amino acids, obtained by

Incubation of cells at suitable growth temperatures, over a period of 2-8 days,

- subsequent lysis,

- Harvest together with the maintenance medium and

- Separation of cell constituents having a molecular weight above 10,000 daltons, by ultracentrifugation / ultrafiltration and

Recovery of the fraction of specific peptides with molecular weights up to 10,000 daltons and the fraction of essential and nonessential amino acids,

The exact composition of the multifunctional drug mixture can not be determined analytically precise, so it is characterized in the present case by its production process. It contains polypeptides of up to 80 amino acids in length, amino acids and salts and minerals. Peptides in the context of the present invention are all possible peptides or peptide chains composed of at least two amino acid residues or thereof To understand derived structures, for example, peptides that are released in the lysis of somatic cells. The peptide fraction may comprise various kinds of peptides, for example substance P (SP), delta-sleep-inducing peptide (DSIP), vasoactive intestinal peptide (VIP), arginine-vasotocin (AVT), oxytocin, samatostatin, interleukin, enkephalins, β- Endorphin, neuropeptide Y, neurotensin, vasopressin, corticotropin-releasing hormones (corticoliberin, CRH)., Thyrotropin-releasing hormones (thyro-liver, TRH). The amino acids are all essential and nonessential amino acids, in particular glycine. Furthermore, the fraction minerals and salts of the elements magnesium, calcium, potassium, zinc, lithium, phosphorus, silicon, manganese, chromium, selenium or molybdenum.

Starting material for the peptide and amino acid fraction of the multifunctional drug mixture are somatic cells. For example, cells of the diploid calf kidney cell line MDBK, chicken fibroblasts or cells of a pig-derived diploid tube epithelial cell line are suitable. For the production of patient-specific active substances, it is also possible, for example, to use endogenous cells which have been obtained from body fluids or tissue, in particular also those which have been obtained from diseased tissue or body fluids, whereby the agent according to the invention is particularly specific and compatible. This plays a major role in pathologically increased cell growth and the detection of messenger substances on the cell membrane to fight cancer.

The cells are incubated at the typical temperatures of the original species from 2O ⁰ C to 39 ° C over a period of 2-8 days, then lysed and harvested with the maintenance medium.

To remove airborne particles, the cell lysate can then be filtered through a filter having a pore size of 0.65 μm. Additional optional filtration through a 0.1 μm pore size filter increases the efficiency of the following ultracentrifugation. The permeate thus obtained is then subjected to ultracentrifugation over a filtration module having an exclusion size of less than 10,000 daltons. The ultracentrifugation preferably has a running time of about 24 hours. In this way, a filtrate is recovered that only substances containing less than 10000 daltons, and thus also the mixture of specific peptides with molecular weights up to 10,000 daltons and / or the fraction with essential and nonessential amino acids. However, filters with other pore sizes are also suitable, the pore size being selected such that the active ingredient mixture has the desired maximum molecular or molecular aggregate sizes of up to 10,000 daltons.

The essential advantage of ultracentrifugation is that in this process, a local concentration of the drug mixture within the centrifuged medium takes place. Furthermore, the ultracentrifugation by the defined spatial distribution of the active ingredients in the centrifuged medium, which is usually dependent on the molecular weight or the spatial structure of the centrifuged components, the ability to selectively remove fractions with a desired range of molecular weights or spatial structures from the medium.

Preference is given to using a multifunctional active ingredient mixture of a fraction of specific peptides having a relative molar mass of from 200 to 6,000 daltons. This mixture is obtained by concentration by a factor of 1000 of the recovered fraction with proteins smaller than 10,000 daltons by physical means.

In another embodiment, the multifunctional drug mixture further comprises

- energized silicon nanoparticles, zeolites, bentonites, montmorillonites, or other mineral substances or mixtures of substances that have been loaded with information for optimizing the control processes of plant or animal cells, cell systems, organs or organisms by irradiating them for about 2 to 5 minutes with 2.45 microwaves Gigahertz were exposed, which causes a change in the crystal structures of the mineral substances.

The process for producing the energized silicon nanoparticles, zeolites, bentonites, montmorillonites or other mineral substances or mixtures in the According to the invention, for the preparation of the drug mixture, will be explained below by way of example.

Both zeolites with a diameter of less than 100 micrometers and finished nanoparticles and microparticles with SiO _{2 of} the product series Köstrosol (trademark) of the Chemiewerk Köstritz were used.

The particles used were exposed to different doses / pulses of microwaves through the use of a magnetron with the frequency of 2450 megahertz, which leads to changes in the crystal lattice and to the acquisition of information about the microwaves, which can be varied according to the destination and indication. One of the most physiological pulse frequencies crystallized out, it is the Schumann frequency of 7.83 Hertz. Others are also possible and dependent on the indication, all possibilities are within the scope of the present invention.

Preferably, a special rosacea with a particle diameter of 7 nanometers is used which is able to loosely bind to fabrics of similar particle size and to serve as transporters for the preferred materials to the target site. At the destination it comes to the transmission of the applied vibration through the particles. The cell / cell systems take these up via the gel-sol formulation and get adhesions or include the described active ingredient mixture or its fractions, or the charged amino acid glycine, which is then similar to the mode of action of substance P (Hecht / Oehme et al. ) acts, applied.

The interaction of mineral, charged particles and the change in the behavior of the organic constituents, as listed in the present invention, in particular the altered behavior of the amino acid glycine (neurotransmitter), allows completely new indications. The mineral component serves as data and information carrier of different vibration quantities, which are mediated in a gel-sol formulation (like all body fluids) by the organic components in the nano- and micro-range of cells and cell assemblies. The production is extremely inexpensive and possible side effects can be largely excluded.

Application - indications:

The present invention further encompasses the use of active substance mixtures described here for the preparation of pharmaceutical compositions for the treatment, prophylaxis and metaphylaxis of medical indications selected from the following list:

Injuries to the nerve tracts; all indications that are described in traditional Chinese medicine for acupuncture; Stroke or other damage to the central nervous system, and the consequent effects on cell systems, organs and organism; Disturbance and failure of the stimulus conduction; disturbed biofuels; Cancers; Viral diseases.

Application method and dosage:

The application of the pharmaceutical compositions according to the invention is preferably carried out by Akujektur (registered trademark, E. Tech). In acupuncture, microliter or sub-microliter volumes of pharmaceutical compositions are injected into the nerve meridians described in traditional acupuncture. Another possibility is to apply the acupuncture needle by immersing it in prepared GeI-SoI formulation before the puncture. An application with known, pressure-based (Rösch) methods of percutaneous injection is also suitable. The dosage of the described ingredients is in the lower micro range.

The pharmaceutical compositions of the present invention revolutionize the treatment options for repairing damaged tissues, and particularly nervous tissue, as well as damaged stimuli to muscles, tendons, and ligaments, in the full range of applications provided by acupuncture. The therapeutic effect of the peptides and amino acids is on the one hand directly increased by the, impressed by the mineral particles information, on the other hand allows the addition of the information-carrying mineral particles and a precise control of the properties of the pharmaceutical Composition. The advantages of the treatment according to the invention are that the active substance entry is negligibly small, the restoration (not in every case, therefore BEQUOL) occurs in comparatively short periods of time or a significantly better quality of life becomes apparent after said damage. The effect on the CNS should also play a very important role in this, as subtle messenger substances are excreted which accelerate the healing process, which suggests a very wide range of applications with almost no side effects. This method is therefore also predestined for a "psycho-neuro-immuno (cancer) therapy, which covers the entire spectrum of modes of action and can be practiced additionally or alone, excluding or minimizing the known serious side effects of chemotherapy with cytotoxins. The physical component and the immunologically active components have the consequence that the barrier to the tumor can be overcome much easier.

It was completely surprisingly found the advantageous suitability of the multifunctional active ingredient mixtures as adjuvants to conventional vaccines for the production of vaccines, which goes well beyond the previous findings on the modes of action of multifraktionellen defense modulators, as well as the effect of macrological particles addition.

The present invention therefore furthermore comprises the use of a mixture of active substances according to the invention for the preparation of an adjuvant with preventive and therapeutic properties for a virus vaccine or a vaccine for the therapy or prophylaxis of body cells which have degenerated in their division rate.

The preventive and therapeutic properties of the active ingredient mixture according to the invention for its suitability as adjuvant to a conventional virus vaccine or a vaccine for the therapy or prophylaxis of degenerated in their division rate body cells is due, inter alia, that it anti-inflammatory, circulation-promoting, absorption and permeability stimulating, spasmenlösend, immunomodulating, disstress-reducing, eustreßstimulierend and homeostasis regulating acts. In particular, the dose-response relationship of the active compound mixture according to the principle of the hyperbola according to the invention allows the specific inhibition of the harmful interaction of one or more substances of the vaccine with endogenous substances or components of the immune system. The advantage of the invention compared to a linear dose-effect relationship is that after saturation of the body's own binding sites with drug substance no further enrichment of drug substance at the destination takes place, but the drug substance is rapidly eliminated from the body and thus overdoses are avoided even at high concentrations.

As the application form all common forms of administration are suitable for vaccines, wherein the adjuvant before the vaccine and / or preferably together with the

Vaccine is administered, in particular per os. But also an application after the

Administration of the vaccine is suitable for certain applications.

Primarily, the intranasal and sublingual forms come into question, an intramuscular one

Application, for example by injection is also possible.

In order to take advantage of a specific mixture smaller than 10 kDa, the intranasal form is preferred, which is a fast, effective and simple

Application possible.

The effect of the universal adjuvant in intranasal administration occurs in a few

Minutes and thus ensures effective mucosal protection, or causes the stimulation of the immune system or combats already adhering pathogens already at the entry point.

In view of the increased dangers of viral infections and their rapid spread, the universal adjuvant is an effective agent, which is also readily available.

Examples

Example 1 :

Conglomerates of the invention were used in nerve meridians, as in the

Acupuncture are described (in the microliter range, some below.). This In patients with disturbed conduction of the nerves (paraplegia, post stroke) the effect was very startling: in the short time (4-8 weeks - longer in observation, therapy) the quality of life unexpectedly improved and the patients are very positive about further treatment Although concomitant therapies were not excluded, hydrogels containing nanoparticles were applied via the skin / mucosa from another invention, which were very helpful and prompted by the patients because the composition was chosen so that the active components in a GeI sol As with all body fluids in humans (mammals), the absorption of the active components was excellent, especially the EMF-modified glycine and silicon nanoparticles (energized.

Additional treatment with a nasal spray of similar composition brought psychological stability, as mentioned in the patent application DE102005027905.8 or PCT / DE2005 / 001073. The focus here was not on the biologicals, but on the altered neurotransmitter glycine and its substance P-like action, as described by Hecht and Oehme et al. have been described.

The combination of TCM and nanotechnology described here represents a significant step in the development of fundamentally new methods of medical treatment that will be of great importance in the future.

Example 2:

An unwanted positive "side effect" was the resolution of 10 years of tinnitus, suggesting further unanticipated applications, and further research in this area has already begun in collaborative projects with high profile medical care centers, open to the latest insights and their applications The most famous patient with an improved quality of life is Roy Hörn from Las Vegas, who testified with gratitude (see media response). Example 3:

For use as an adjuvant, mixtures of substances of 0-10 kDa were completely unexpectedly suitable in practice, the suitability being confirmed by exemplary embodiments.

The use as the sole immunomodulator fades into the background for this application. Application of an antigen with the addition of the adjuvant / immunomodulator according to the invention having a viricidal, bactericidal and / or fungicidal action produces the following effects:

a) The body is able to have a general immune response to all viruses within a few hours (4-8h);

b) The immune response to the applied antigen is significantly improved, higher titers are the result;

c) An antigen application into an existing, latent infection does not lead to the generalization of the disease process;

d) After 6-8 days the general protection against viruses by the "universal adjuvant" diminishes and the vaccine protection by the antigen sets in;

e) In severe disease courses would be an application only with the "universal adjuvant", while the beginning, forming immunity displayed, it would be equal to a booster effect, an overdose is not possible, a resistance formation excluded.

Claims

claims

1. Multifunctional drug mixture comprising

Incubation of cells at suitable growth temperatures, over a period of 2-8 days,

- subsequent lysis,

- Harvest together with the maintenance medium and

- Obtaining the fraction of specific peptides with molecular weights up to 10,000 daltons and the fraction of essential and nonessential amino acids.

2. Active substance mixture according to claim 1, further comprising

- Energized silicon nanoparticles, zeolites and / or bentonites, montmorillonites or other mineral substances and / or mixtures of substances which have been loaded with information to optimize the control processes of plant or animal cells, cell systems, organs or organisms by applying microwave radiation of a specific dose and frequency get abandoned.

3. Multifunctional drug mixture according to claim 1-2, wherein the separation by means of ultracentrifugation / ultrafiltration with a filter and / or takes place during a period of 24 hours.

4. Multifunctional drug mixture according to claim 1-3, wherein a fraction of specific peptides having molecular weights between 200 and 6000 daltons and / or a fraction with essential and nonessential amino acids is used.

5. Use of an active substance mixture according to claim 1-4 for the preparation of a pharmaceutical composition for the treatment, prophylaxis and metaphylaxis of a medical indication selected from the following list:

6. Use of a drug mixture according to claim 1-4 for the preparation of an adjuvant with preventive and therapeutic properties for virus vaccines or vaccines for the therapy or prophylaxis of degenerated in their division rate body cells.

Use according to claim 5 or 6, wherein the pharmaceutical composition or adjuvant is suitable for administration by acupuncture.

8. Use according to claim 5 or 6, wherein the dose-response relationship of the pharmaceutical composition or the adjuvant follows the principle of a hyperbolic curve, whereby an overdose is excluded.

9. Use according to claim 6, wherein the adjuvant itself is hardly antigenic but stimulates the immune system to enhance the response to the vaccine.

10. Use according to claim 6, wherein the virus vaccine or the vaccine for the therapy or prophylaxis of degenerated in their division rate body cells is a biologically or genetically engineered agent.

11. Use according to claim 6, wherein the virus vaccine or the vaccine for the therapy or prophylaxis of degenerated in their division cell body cells consists of or comprises individual protein or genetic fragments.

Use according to claim 6, wherein the virus vaccine or the vaccine for the therapy or prophylaxis of body cells degenerated in their division rate consists of or comprises killed or attenuated pathogens.

13. Use according to claim 6, wherein the drug mixture is used in excess in comparison to the virus vaccine or the vaccine for the therapy or prophylaxis of degenerated in their division cell body cells.